To better understand the role of CD5 in CTCL and evaluate its potential as a therapeutic agent, we assessed CD5 gene expression on malignant CD4 T cells in MF patients utilizing single-cell RNA sequencing (scRNA-seq) strategies. This evidence concerns the gene CD5 and primary cutaneous T-cell non-Hodgkin lymphoma.